EZRA

Reliance Global Group, Inc.

8 filings tracked

financialsinsurance brokerageMICRO (<$300M)

Signal Magnitude Chart

bullish

bearish

neutral

Signal Timeline

bearishMay 7

Reported a consolidated net loss of $1.47 million for the quarter.

earnings miss

70%

bullishMay 7

Insurance segment net income grew 39% due to aggressive cost cutting.

margin expansion

60%

bullishMay 7

Secured a $50 million equity line of credit to fund M&A and operations.

capital raise

50%

neutralMay 7

Initiated strategic investments in Enquantum and Innervate as part of Scale51 strategy.

acquisition

40%

bearishMay 7

Reported a consolidated net loss of $1.47 million for the quarter.

earnings miss

70%

bullishMay 7

Insurance segment net income grew 39% due to aggressive cost cutting.

margin expansion

60%

bullishMay 7

Secured a $50 million equity line of credit to fund M&A and operations.

capital raise

50%

neutralMay 7

Initiated strategic investments in Enquantum and Innervate as part of Scale51 strategy.

acquisition

40%

bearishMay 7

Reported a consolidated net loss of $1.47 million for the quarter.

earnings miss

70%

bullishMay 7

Insurance segment net income grew 39% due to aggressive cost cutting.

margin expansion

60%

bullishMay 7

Secured a $50 million equity line of credit to fund M&A and operations.

capital raise

50%

neutralMay 7

Initiated strategic investments in Enquantum and Innervate as part of Scale51 strategy.

acquisition

40%

bearishMay 7

Reported a consolidated net loss of $1.47 million for the quarter.

earnings miss

70%

bullishMay 7

Insurance segment net income grew 39% due to aggressive cost cutting.

margin expansion

60%

bullishMay 7

Secured a $50 million equity line of credit to fund M&A and operations.

capital raise

50%

neutralMay 7

Initiated strategic investments in Enquantum and Innervate as part of Scale51 strategy.

acquisition

40%

bearishMay 7

Reported a consolidated net loss of $1.47 million for the quarter.

earnings miss

70%

bullishMay 7

Insurance segment net income grew 39% due to aggressive cost cutting.

margin expansion

60%

bullishMay 7

Secured a $50 million equity line of credit to fund M&A and operations.

capital raise

50%

neutralMay 7

Initiated strategic investments in Enquantum and Innervate as part of Scale51 strategy.

acquisition

40%

bearishMay 7

Reported a consolidated net loss of $1.47 million for the quarter.

earnings miss

70%

bullishMay 7

Insurance segment net income grew 39% due to aggressive cost cutting.

margin expansion

60%

bullishMay 7

Secured a $50 million equity line of credit to fund M&A and operations.

capital raise

50%

neutralMay 7

Initiated strategic investments in Enquantum and Innervate as part of Scale51 strategy.

acquisition

40%

bearishMay 7

Reported a consolidated net loss of $1.47 million for the quarter.

earnings miss

70%

bullishMay 7

Insurance segment net income grew 39% due to aggressive cost cutting.

margin expansion

60%

bullishMay 7

Secured a $50 million equity line of credit to fund M&A and operations.

capital raise

50%

neutralMay 7

Initiated strategic investments in Enquantum and Innervate as part of Scale51 strategy.

acquisition

40%

bullishMar 26

Aggressive roll-up of insurance and benefits agencies to scale revenue.

acquisition

70%

bearishMar 26

Frequent amendments to credit facilities and promissory notes suggest liquidity stress.

debt restructure

60%

bearishMar 26

Heavy use of warrants and ATM offerings creates significant overhang for shareholders.

dilution risk

80%

Filing History

10-QMay 7, 2026

The 10-Q paints a picture of a company at a critical crossroads, attempting to pivot from a stable but slow-growth insurance model to a high-risk, high-reward technology holding company. The operational improvement in the insurance segment is a positive signal, but it is currently overshadowed by the consolidated net loss and the speculative nature of the new strategic ventures. The success of the "Scale51" model depends entirely on the company's ability to successfully commercialize quantum and life science technologies—areas where it has limited experience. For investors, the immediate focus is on the execution of the reverse stock split and the subsequent ability to maintain the $1.00 minimum bid price. While the $50 million credit facility provides a theoretical safety net, the actual liquidity remains tight. The tension between the organic growth of the insurance engine and the cash-burn of the strategic ventures will determine if EZRA is a visionary transformation or a series of speculative gambles funded by a shrinking core.

10-KMar 26, 2026

The recent 10-K/A filing serves as a critical update to the company's corporate governance, specifically adding a Compensation Recovery Policy to its exhibits. While the filing is primarily administrative, it underscores the company's ongoing efforts to formalize internal controls amidst a period of rapid structural change. The overarching tension for investors remains the trade-off between the company's ambitious M&A trajectory and its fragile financial foundation. Ultimately, the impact of the filing highlights a company in transition. The ability of Reliance Global Group to convert its aggressive acquisition spree into a cohesive, profitable platform will determine if it is a successful turnaround play or a cautionary tale of over-leverage. Investors are left to weigh the potential for a massive re-rating against the very real risk of equity wipe-out due to the company's punitive financing terms.